After British whistleblower Michael Woodford was sacked as CEO of Olympus and revealed the Japanese firm had covered up losses of US$1.7 billion, he mounted a campaign to get his job back.
However, his effort went nowhere, with Japanese financial institutions preferring to stick with the remaining board and several disgraced directors, some of them being sued by Olympus itself.
Now a group of 26 activist lawyers is looking to change Japan’s closed corporate society as the scandal rocks global confidence in the business governance standards of the world’s third-largest economy.
Institutional shareholders “are the reason why these directors are still there, without their support they shouldn’t be,” said Woodford, the first non-Japanese to lead the camera and medical equipment maker. “Despite one of the biggest scandals in history [they] have not spoken one single word of criticism.”
However, shareholder activism is rare in Japan. Instead, institutions tend to have cosy ties with board members and cross-shareholdings are commonplace, creating a network of interests that militates against rocking the boat — on Friday the Tokyo Stock Exchange said it would let the firm stay listed.
Lawyers for Shareholders’ Rights (LSR) is backing an individual Olympus shareholder whose stake is worth only around ¥2.8 million (US$36,000) but who — unlike the institutions — has stood up against the board.
The anonymous man from western Japan is suing the directors who sacked Woodford, demanding they pay Olympus ¥1.34 billion in compensation for the firm’s costs.
Takuro Maekawa, one of LSR’s leading members, said his team — who do not charge for such cases — want to change a culture which “has compromised corporate responsibility and compliance.”
Olympus has admitted that it used over-priced acquisitions and consultancy fees to hide losses it had made on earlier investments dating back to the 1990s.
The company has launched legal action against 19 top current and former executives, including six present board members, among them president Shuichi Takayama, after an independent panel found them responsible for the cover-up.
However, Takayama has not been sacked in disgrace or resigned, instead saying in the past week he would step down only after an extraordinary general meeting in April.
None of Olympus’ major Japanese shareholders have publicly called for him to go. Instead they have quietly reduced their stakes as the share price plunged, with the biggest shareholder, Nippon Life Insurance, only citing unspecified “risks” and “economic rationality” when it said in November it had sold almost two-fifths of its holding.
Maekawa condemned the institutions’ silence as “extremely abnormal.”
LSR is looking at joining Olympus’ own case, he said, to ensure it is properly pursued and “to bring all of the scandal into the light of day.”
The LSR lawyers first started mounting actions on such issues in the early 2000s.
They sued four executive directors of Hitachi Zosen, a leading machinery and infrastructure firm, demanding they reimburse the fines the company had been ordered to pay for bid-rigging, eventually settling for ¥205 million.
They have also taken action against the president of Daiichi Life Insurance, demanding he pay back the expenses he claimed for wining and dining a number of politicians.
However, the Olympus case is by far their most internationally high-profile so far.
“Our objective is not necessarily to help short-term investors make money by demanding a company make profit in every quarter,” Maekawa said. “Individual investors have long been left at a great disadvantage to institutional holders.”
Michikazu Aoi, professor of global management at Meiji University, said the Olympus scandal could have long-term consequences for both the company and the country.
“The Olympus board may be thinking, since the company has the world’s top-notch endoscope technology, that they can withstand the scandal, smoothly handing over the company to the next board, and that the share price will eventually recover,” he said. “But I don’t think things will be so easy.”
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained